Ledipasvir

Ledipasvir, also known as GS-5885; is an inhibitor of the hepatitis C virus NS5A protein and is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg (trade name Harvoni) . The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.

Product Specifications

CAS Number

1256388-51-8

Product Name Alternative

GS5885 | GS-5885 | GS 5885 | Ledipasvir

Field of Research

Pharmacology & Drug Discovery

Purity

>98% (HPLC)

Solubility

DMSO : 50 mg/mL. 56.24 mM; H2O : < 0.1 mg/mL

Smiles

O=C (OC) N[C@H] (C (=O) N1[C@H] (c2ncc (c3cc4C (F) (F) c5c (ccc (c6ccc7nc ([C@H]8N (C (=O) [C@@H] (NC (=O) OC) C (C) C) [C@@H]9CC[C@H]8C9) [nH]c7c6) c5) c4cc3) [nH]2) CC2 (C1) CC2) C (C) C

Molecular Formula

C49H54F2N8O6

Molecular Weight

889

Storage Conditions

Storage temperature: -20°C. Stability: ≥ 2 years

Notes

For research use only.

Other Product Names

Methyl N-[ (2S) -1-[ (6S) -6-[5-[9,9-Difluoro-7-[2-[ (1S,2S,4R) -3-[ (2S) -2- (methoxycarbonylamino) -3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate